<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152035</url>
  </required_header>
  <id_info>
    <org_study_id>SPD465-304</org_study_id>
    <nct_id>NCT00152035</nct_id>
  </id_info>
  <brief_title>Safety of SPD465 in Treating Adults With ADHD.</brief_title>
  <official_title>A Phase III, Multi-center, 12-month, Open-label Safety Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of SPD465 in the&#xD;
      treatment of ADHD. The study will also look at how SPD465 affects sleep.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2005</start_date>
  <completion_date type="Actual">November 7, 2006</completion_date>
  <primary_completion_date type="Actual">November 7, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of safety will be based on the occurrence of treatment emergent AEs and specific evaluation of vitals signs, ECG, laboratory and physical examination.</measure>
    <time_frame>Throughout the study period of approximately 20 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADHD-rating scale (ADHD-RS-IV) taken at the Visit 1 and all visits thereafter.</measure>
    <time_frame>Baseline, Weekly for 4 weeks, and then Monthly for 5 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement scale assessed at Visits 1 through 15/Early Termination (ET).</measure>
    <time_frame>Baseline, Weekly for 4 weeks, and then Monthly for 5 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI) - assessed at Visits 1 through 15/ET.</measure>
    <time_frame>Baseline, Weekly for 4 weeks, and then Monthly for 5 months.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">505</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject satisfied all entry criteria for the antecedent protocol (SPD465-301 or&#xD;
             SPD465-303) and completed a minimum of 4 of the 7 weeks of double-blind treatment&#xD;
             without experiencing any clinically significant adverse events.&#xD;
&#xD;
          -  Subject must be male or non-pregnant female who agrees to comply with using acceptable&#xD;
             contraceptive methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject was terminated from antecedent protocol (SPD465-301 or SPD465-303) for&#xD;
             non-compliance and/or experienced a serious adverse event or adverse event resulting&#xD;
             in termination from the protocol.&#xD;
&#xD;
          -  Comorbid psychiatric diagnosis with significant symptoms such as Axis II disorders or&#xD;
             severe Asix I disorders.&#xD;
&#xD;
          -  History of seizure, tic disorder, or a current diagnosis and/or family history of&#xD;
             Tourette's Disorder.&#xD;
&#xD;
          -  Females who are pregnant of lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

